Holen Sie sich die Stockscreener-App
684.89
1.64%
11.07
Handel nachbörslich:
685.71
0.82
+0.12%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$673.82
Offen:
$675.855
24-Stunden-Volumen:
1.93M
Relative Volume:
0.68
Marktkapitalisierung:
$253.24B
Einnahmen:
$45.20B
Nettoeinkommen (Verlust:
$6.87B
KGV:
37.65
EPS:
18.1888
Netto-Cashflow:
$6.75B
1W Leistung:
+0.81%
1M Leistung:
+1.47%
6M Leistung:
+45.81%
1J Leistung:
+19.63%
1-Tages-Spanne:
$674.37
$685.48
1-Wochen-Bereich:
$661.30
$705.78
52-Wochen-Spanne:
$435.27
$705.78
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
684.89 | 253.24B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
232.97 | 163.77B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
404.90 | 58.36B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
175.96 | 49.61B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
273.60 | 45.03B | 16.63B | 1.39B | 2.12B | 8.0674 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-09 | Hochstufung | UBS | Neutral → Buy |
| 2026-09-03 | Eingeleitet | CLSA | Outperform |
| 2026-06-26 | Fortgesetzt | Bernstein | Mkt Perform |
| 2026-06-11 | Eingeleitet | Piper Sandler | Neutral |
| 2026-06-03 | Herabstufung | HSBC Securities | Buy → Hold |
| 2026-06-02 | Fortgesetzt | Wolfe Research | Outperform |
| 2026-05-15 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2026-03-27 | Eingeleitet | DZ Bank | Buy |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-12-01 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Eingeleitet | William Blair | Outperform |
| 2025-07-24 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-03-18 | Fortgesetzt | Citigroup | Neutral |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-06 | Fortgesetzt | Citigroup | Buy |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
| 2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Bestätigt | Barclays | Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Fortgesetzt | Barclays | Overweight |
| 2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Bestätigt | Needham | Buy |
| 2020-04-23 | Bestätigt | Needham | Buy |
| 2020-01-31 | Bestätigt | Needham | Buy |
| 2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-25 | Bestätigt | Needham | Buy |
| 2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-05-23 | Bestätigt | Needham | Strong Buy |
| 2019-04-22 | Bestätigt | Needham | Strong Buy |
| 2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
RBC Raises Price Target on Thermo Fisher Scientific to $730 From $580, Keeps Sector Perform Rating - www.marketscreener.com
Deutsche Bank Adjusts Thermo Fisher Scientific PT to $750 From $720, Maintains Buy Rating - www.marketscreener.com
Stifel Adjusts Price Target on Thermo Fisher Scientific to $775 From $650 - marketscreener.com
Barclays Adjusts Price Target on Thermo Fisher Scientific to $775 From $750 - marketscreener.com
Company News for Oct 22, 2026 - Zacks Investment Research
TMO Q3 deep dive: pharma demand, AI integration, and end-market recovery drive momentum - Yahoo Finance
Thermo Fisher Scientific Hits $12.14 Billion in Q3 Revenue as Innovation Fuels Double-Digit Earnings Growth - BioSpectrum Asia
Thermo Fisher Scientific (TMO) Stock Faces A Q3 Earnings Disconnect - Yahoo Finance
Thermo Fisher Scientific Inc Stock 12‑Month Price Target Raised to $701.64, Implies 2% Upside - TradingView
Thermo Fisher: You Don't Need A Microscope To See The Growth Anymore (NYSE:TMO) - Seeking Alpha
Thermo Fisher Scientific Inc (TMO) (Q3 2026) Earnings Call Highl - GuruFocus
Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors - Yahoo Finance
Thermo Fisher Scientific Tops Q3 2026 Profit Forecast With $6.68 EPS - AlphaStreet
Thermo Fisher Scientific Gains 4.3% on Q3 Earnings Beat - 24/7 Wall St.
Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors - The Motley Fool
Why Is Thermo Fisher Scientific Stock Trading Higher Today?Thermo Fisher Scientific (NYSE:TMO) - Benzinga
Thermo Fisher Scientific Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
Thermo Fisher reports strong 3rd-quarter results - WFMZ.com
Nasdaq Gains 1%; Thermo Fisher Scientific Posts Upbeat Earnings - Benzinga
Thermo Fisher Scientific Reports Third Quarter 2026 Results - BioSpace
Thermo Fisher stock gains on Q3 beat (update) (TMO:NYSE) - Seeking Alpha
Thermo Fisher Scientific Tops Q3 2026 Profit Forecast With $6.68 EPS - AlphaStreet
Thermo Fisher Q3: The Recovery Is Real, And I'm Still Buying (NYSE:TMO) - Seeking Alpha
Thermo Fisher Q3 2026 earnings show adjusted EPS up 15% to $6.68 - Quartz
Thermo Fisher Scientific Reports 9% Revenue Growth as Third-Quarter Earnings Beat Estimates - Yahoo Finance
Thermo Fisher Scientific Inc. reports results for the quarter ended September 30Earnings Summary - TradingView
Thermo Fisher Scientific Q3 2026 Earnings Call Transcript - Benzinga
Thermo Fisher Scientific Releases Q3 2026 Earnings Results - AlphaStreet
Is Thermo Fisher Scientific Inc (TMO) Overvalued After Q3 Earnin - GuruFocus
Thermo Fisher Scientific (TMO) Tops Q3 Earnings and Revenue Estimates - Zacks Investment Research
Thermo Fisher Scientific (TMO) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance Singapore
Thermo Fisher Scientific Reports Third Quarter 2026 Results - Business Wire
Thermo Fisher Scientific Inc. stock rises Tuesday, outperforms market - MarketWatch
Why Thermo Fisher (TMO) Could Beat Earnings Estimates Again - Zacks Investment Research
Top Wall Street Forecasters Revamp Thermo Fisher Scientific Expectations Ahead Of Q3 Earnings - Benzinga
Thermo Fisher Scientific Inc. stock: results due October 21 ahead of Xetra open - ad-hoc-news.de
Thermo Fisher (TMO) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
Thermo Fisher Scientific Inc. stock falls Monday, underperforms market - MarketWatch
Forge’s Fierce Life Sciences Announces 2026 Fierce Innovation Awards Finalists and Unveils the Fierce Vanguard Gala - GlobeNewswire Inc.
Thermo Fisher Scientific Inc. expected to post earnings of $6.40 a shareEarnings Preview - TradingView
Beat the Market the Zacks Way: Valero Energy, Hagerty, Palantir in Focus - Zacks Investment Research
Clinical Trial Supplies Market Forecasts Growth from $5.7 Billion (2025) to $10.7 Billion by 2033, Profiling Thermo Fisher Scientific, Catalent, Almac Group, UPS Healthcare & 6 Other Key Players - GlobeNewswire Inc.
Thermo Fisher Scientific (TMO) Is Building A Bigger Role In Precision Diagnostics - Yahoo Finance
Thermo Fisher Scientific Introduces the Thermo Scientific™ EMPAD™ - The National Law Review
Thermo Fisher Scientific (TMO) Stock Gets Fair Value Bump After Q2 Driven Analyst Target Increases - Yahoo Finance
Learn Why The Bull Case For Thermo Fisher Scientific Stock Could Change Following Omics Demand Growth - Yahoo Finance
Thermo Fisher Scientific Outperforms on Strong Results and Life Sciences Recovery - Yahoo Finance
Academic and Government Spending Powers Thermo Fisher (TMO) - Yahoo Finance
Thermo Fisher Scientific (TMO) Q3 2026 Preview: EPS Est. $6.40, Reports October 21 - AlphaStreet
If You Invested $1000 in Thermo Fisher Scientific a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Thermo Fisher Scientific Inc-Aktie (TMO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pettiti Gianluca | Officer |
Aug 31 '26 |
Proposed Sale |
614.38 |
4,133 |
2,539,233 |
0 |
| Pettiti Gianluca | President & COO |
Aug 31 '26 |
Sale |
614.38 |
4,133 |
2,539,233 |
23,216 |
| CASPER MARC N | Chairman & CEO |
Aug 24 '26 |
Sale |
627.05 |
275 |
172,439 |
123,925 |
| CASPER MARC N | Chairman & CEO |
Aug 24 '26 |
Option Exercise |
309.63 |
275 |
85,148 |
124,200 |
| CASPER MARC N | Officer |
Aug 24 '26 |
Proposed Sale |
627.05 |
275 |
172,438 |
0 |
| CASPER MARC N | Chairman & CEO |
Aug 21 '26 |
Sale |
626.92 |
10,000 |
6,269,153 |
123,925 |
| CASPER MARC N | Officer |
Aug 21 '26 |
Proposed Sale |
626.91 |
10,000 |
6,269,123 |
0 |
| CASPER MARC N | Officer |
Aug 20 '26 |
Proposed Sale |
629.27 |
10,000 |
6,292,653 |
0 |
| CASPER MARC N | Chairman & CEO |
Aug 20 '26 |
Option Exercise |
309.63 |
10,000 |
3,096,300 |
133,925 |
| CASPER MARC N | Chairman & CEO |
Aug 20 '26 |
Option Exercise |
309.63 |
10,000 |
3,096,300 |
133,925 |
1.07%
2.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):